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Research article 
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Abstract: Epigenetic silencing is the reversible inactivation of a gene transcription which occurs as a 
result of changes in the structure of the chromatin that can be successfully inherited from parent to 
daughter cells. It involves non-genetic mutations within the genome, as well as post-transcriptional 
and post-translational mechanisms. Existence of these mechanisms at various levels warrants their 
role in development and disease and thus it is crucial to study different factors and mechanisms of 
silencing. The aim of our study was to establish a method for rapid screening for the loss of 
epigenetic silencing in mammalian cells, to identify factor(s) involved in epigenetic silencing, and to 
get insights into their mechanism of action. For this purpose, we used RNAi screening approach 
using shRNAs that targeted our genes of interest. We employed a modified mouse cell line which 
contained a GFP transgene under the control of CMV promoter which has been silenced by 
epigenetic modifications. Our screening identified several proteins as epigenetic silencing regulators 
including Kat5/Tip60, an acetyltransferase of MYST family of proteins. To characterize its function, 
we performed preliminary experiments using microscopy and Western blot analysis of histone marks. 
We observed changes in H4 acetylation levels in Kat5/Tip60 knockdown cells. Our study thus serves 
as a pilot for a genome-wide silencing screening using mammalian cells, and provides preliminary 
results suggesting that Kat5 can be considered as a silencing factor, which, we propose, could 
function by maintaining H4 acetylation patterns. 
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Abbreviations 
SEM = Standard error of the mean; RNAi = RNA interference; shRNAs = short-hairpin RNAs; GFP 
= Green Fluorescent Protein; FACS = Fluorescent Activated Cell Sorting; MOI = Multiplicity of 
Infection; TSA = Trichostatin-A; scrRNA = TagRFP-shRNA; CRISPR = Clustered, regularly 
interspaced, short palindromic repeats 
 
1. Introduction 
Epigenetics refers to heritable changes in gene expression that can be observed irrespective of 
the changes in the DNA sequence [1]. Such processes can have varied outcomes depending on the 
structural organization of the chromatin. An “open chromatin”, technically termed euchromatin, 
would assist the expression of a gene while heterochromatin (“closed chromatin”), would result in 
the loss of expression [2]. Recent efforts allowed to model gene expression, taking into account 
multiple factors, including nucleosome dynamics, and binding of activators and repressors [3]. Loss 
of gene expression, referred to as epigenetic gene silencing, is one of the commonly observed 
phenomenon in disease mechanisms [4]. It can be affected by non-coding RNAs and nuclear 
remodelling factors, in addition to modification of cytosine and histone tails [5], eventually resulting 
in loss of gene transcription or inhibition of translation [6]. 
Research in epigenetics has been on a wide variety of mechanisms and regulatory functions. For 
instance, particular modifications or silencing marks, such as the abundance of H2A ubiquitylation or 
H3 lysine 27 (H3K27) trimethylation have been observed in regions of double stranded breaks. One 
of the most commonly studied roles of epigenetics in this aspect is the DNA repair mechanisms. 
Implications of interplay between chromatin modifying factors and repair mechanisms have been 
well studied especially in the case of DOT1L, HIRA and FACT [7]. Furthermore, the role of 
epigenetic factors in pluripotency and development have also been increasingly researched. The 
major pluripotency factors (Oct4, Sox2 and Nanog [OSN]) regulate the expression of genes which 
aids the transcription of Polycomb and MLL complex components. In turn, these complexes repress 
transcription factors in a lineage-specific manner. Such co-operation between the repressive 
complexes and OSN factors are significant for the maintenance of pluripotent state [8]. In addition, 
non-coding RNAs such as micro-RNAs (miRNAs) and long non-coding RNAs (lncRNAs) have been 
a major focus of interest with respect to developmental mechanisms. With advancements in RNA-
sequencing methodologies and CRISPR system, a number of such non-coding RNAs are being 
identified and characterized [9].  
Nonetheless, the ubiquitous nature of epigenetics have broadened its focus and research aims to 
disease mechanisms and drug resistance. Of the many diseases that can be associated with 
epigenetics, the most common and widely studied have been cancers. Cancers can arise due to the 
activation of an oncogene or by repression of tumour-suppressors, such as CDKN2A 
hypermethylation, which leads to lung cancer [10]. As mentioned above, different mechanisms such 
as DNA and histone modifications and RNAi (RNA-interference) are potential regulators of gene 
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expression and are thus involved at different stages of carcinogenesis [11]. Apart from cancers, there 
are number of other diseases from cardiovascular to autoimmune disorders which occur due to 
various epigenetic events. HOTAIR, a well-known non-coding RNA, which usually plays a role in 
repression of HOX genes by recruiting Polycomb complex, has been observed to be involved in 
aortic calcification due to its role in stress response and as a repressor of calcification genes [12]. 
Similarly, global decrease in histone acetylation at H3 and H4 of CD4+ T cells, have been associated 
with systemic lupus erythematosus (SLE), an autoimmune disorder [13]. Additionally, epigenetics 
would be able to provide a comprehensive understanding of personalized medicine due to its role in 
drug resistance. Cetuximab, a drug that is administered for colon cancer, is ineffective for patients 
with mutated BRAF and KRAS genes. However, some patients with wild-type copy of those genes, 
also do not show any response to the drug. SIRT2, a histone deacetylase, has been identified as a 
marker for drug resistance in such cases. SIRT2 acetylates MEK, a downstream component of KRAS 
pathway, which inhibits its phosphorylation activity. Loss of SIRT2 would thus result in MEK 
phosphorylation of ERK, another component of KRAS pathway, resulting in activation of 
transcription and in turn conferring drug resistance [14]. 
 
Figure 1. Hypothesis of the research study: The modified cell-line contains an 
epigenetically silenced CMV promoter (marked in red) which controls a GFP 
reporter (marked in white). Administration of shRNA to knockdown a factor of 
interest, would result in the de-repression of the promoter (marked in white), if that 
particular gene is involved in epigenetic mechanism and thus should express GFP 
(marked in green). While when a non-targeted shRNA is used, no expression of 
GFP should be observed. 
Furthermore, current research have complicated the epigenetic landscape by hypothesizing the 
role of lipids in gene regulation [15] and the observation of factors involved in both repression and 
activation. For instance, H3.3, a variant of histone H3, has generally been associated with 
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transcriptional activation [16]. However, recent studies [17] suggested that H3.3 could act as a 
negative regulator of gene expression. In support of this, another study [18] observed that H3.3 is 
being deposited in the heterochromatic regions by ATRX and gets enriched with H3K9me3, thus 
potentially posing a negative regulatory role. Such complex nature of epigenetics and its involvement 
in myriads of processes, substantiates the comprehensive elucidation of its factors and their 
mechanisms. The aim of our study was to identify factor(s) involved in epigenetic silencing and to 
possibly get insights into their molecular function. We used mouse cells, termed C127, which 
contained a GFP transgene, downstream of a CMV promoter that has been epigenetically silenced. 
Short-hairpin RNAs (shRNAs) were used for knocking-down targets of interest by RNAi mechanism. 
We hypothesized that knockdown of targets involved in silencing should result in de-repression of 
promoter and hence the expression of GFP (Figure 1). Our screen identified seven hits out of which, 
KAT5/Tip60 was particularly interesting due to its role as an acetyltransferase [19]. Based on earlier 
reports and our preliminary experiments, we were able to suggest that KAT5/Tip60 positively 
regulates silencing by maintaining the patterns of histone H4 acetylation. 
2. Materials and Methods 
2.1. Cell lines and cell culture 
Genetically modified mouse mammary adenocarcinoma, referred to as C127 was used for 
screening and analysis (kindly provided by Dr. Elisabeth Martinez). These cells contained a GFP 
reporter transgene under the control of CMV promoter that has been silenced. De-repression of CMV 
promoter and hence expression of GFP was observed after treatment with known modulators such as 
Trichostatin-A (TSA). The integration of GFP was a single insertion at Chromosome 4 (Dr. Elisabeth 
Martinez, personal communication). The methodology for the production of this cell-line has been 
explained in [20].  
The cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Life Technologies) 
containing 1% v/v Penicillin/Streptomycin with 10% Fetal Calf Serum (FCS). The GFP leakage was 
maintained to be less than 5% and was checked during each experiment.  
2.2. Lentiviral particles 
Mission® shRNA lentiviral particles were purchased from Sigma-Aldrich. The targets of 
interest for screening were chosen based on previous implications, role in cancer, homologs and 
presence of putative domains that can bind to different modifications. Table 1 gives the list of genes 
that were chosen for screening while their corresponding shRNA sequences are given in 
Supplementary S1 and plasmid map in Supplementary S2.  
2.3. Fluorescence-activated cell sorting (FACS) 
GFP readout was analyzed by FACS. Cells were collected by trypsinization and re-suspended in 
PBS and analyzed using BD LSRFortessa™ and BD FACSDiva™ software (BD Biosciences).  
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Table 1. List of genes that were chosen for the screening. 
Targets of interest 
Wdhd1 Pou5f1 Sirt1 Pwp1 Nop58 
Brd2 Uhrf1 Rnf3 Tal1 Ehmt2/G9a 
Parp2 Smarca4 Brd4 Smarcad1 Phf1 
H2afy Tdrd3 Dot1l Smyd2 Sp110 
Piwil4 Prdm16 Nsd1 Mds1 Uhrf2 
Chd4 Kat5 Brd3 Rag2  
2.4. RNAi screening 
Multiplicity of infection (MOI), puromycin selection (Gibco® Life technologies) and polybrene 
(Millipore, CAT#TR-1003-G) concentration were assessed according to manufacturer’s protocol. 
Cells at a concentration of 20,000 cells/well (counted using Coulter counter) were seeded onto a 96-
well flat bottom plate (Griener CELLSTAR®) and transduced according to manufacturer’s 
instructions. 48 hours after puromycin treatment, they were analysed by FACS. Tag-RFP shRNA 
(scrRNA in further contexts) was used as negative control and Trichostatin-A (TSA) at 4μM for 24 
hours was used as positive GFP control. Once the candidate hits were identified, cell lines with stable 
knockdowns were obtained following manufacturer’s instructions. 
2.5. RNA extraction and Quantative real-time PCR (qRT-PCR) 
RNA was extracted using TRIzol® reagent (Invitrogen) and its concentration measured using 
Qubit® 2.0 Fluorometer. RNA was treated with DNA-free™ kit to eliminate DNAse contamination 
(Ambion® Life Technologies). cDNA was synthesized using Promega Reverse Transcription 
following manufacturer’s protocol. 
For qRT-PCR, LightCycler® 480 SYBR Green I Master (Roche) was used with LightCycler® 
480 Instrument II (Roche). Primer sequences and the program followed are given in Supplementary 
S3. 
2.6. Immunofluorescence (IF) staining and analysis 
Cells cultured on a coverslip were fixed with 1% Paraformaldehyde (PFA) for 10min at room 
temperature (RT) followed by permeabilization with 0.2% Triton X-100 for 10min at RT and 
blocked using 5% donkey serum in PBS for 15min in a humidified chamber. This was followed by 
primary and secondary antibody incubation for 1hr each with PBS washes between them. H3K9me3 
(a gift from Hiroshi Kimura) mouse monoclonal antibody at 1:100 dilution with PBS was used as the 
primary antibody while Cy5 (Invitrogen) at 1:500 dilution with PBS was used as secondary antibody. 
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Vectashield® (Vector laboratories) was used as mounting medium and DAPI was used to visualize 
the nuclei. 
Images were taken using Zeiss Axioplan 2 microscope at 100x (Zeiss Plan-APOCHROMAT 
100x/1.4 oil DIC) using iVision software and Zeiss observer Z1 microscope at 10x (Zeiss FLUAR 
10x/0.50) using MetaMorph v7.8.8.0 (Molecular Devices). CellProfiler v2.1.1 [21] was used for 
analysing the images. The intensities were calculated at 10x magnification by taking the average at 5 
different positions with a minimum of 200 cells each.  
2.7. Extraction of histones 
Cells were cultured on a 147mm dish and scraped in PBS when they reach 95–100% confluency. 
Histones were extracted using acid extraction method followed in [22].  
2.8. Western blot 
10μg of histones were run on 10–20% Novex® Tricine gel and transferred on to a 0.20μm 
PVDF membrane (GE Healthcare Life Sciences) using Trans-Blot® SD Semi-Dry Transfer cell 
(Bio-Rad) following manufacturer’s protocols (Buffer composition: Supplementary S4). 
The following monoclonal histone antibodies (kind gift from Hiroshi Kimura) were used at 
1:1000 dilution: i) H3K9me3 (CMA318); ii) H4K5Ac (200Nb 4A7); iii) H4K8Ac (200Nd 53B2); iv) 
H4K12Ac (200Nf 50B3); and v) H4K16Ac (200f 27F10). Histone H3 antibody (ab1791, Abcam) 
was used as a loading control. The secondary antibody was Goat anti-mouse HRP conjugate (Thermo 
scientific). NuGlo ECL substrate (Alpha Diagnostics International) was used followed by detection 
using LI-COR Odyssey® Fc system. Densitometric analysis was performed using Image Studio™ 
software v3.1 (LI-COR Biosciences). 
2.9. Statistical tests 
All experiments were done in triplicates, except Western blot which was done in duplicate. 
Screening data was log transformed and one-tailed t-test was performed to identify the significant 
hits. A 50% quartile cut-off for number and percentage of GFP cells was also calculated on the 
screening data. One-tailed Student’s t-test was performed for qPCR and Western blot data. All 
statistical calculations and graphs were obtained using GraphPad PRISM® v6. 
3. Results 
3.1. KAT5, a candidate hit from the screening 
RNAi screen was set up and optimization was performed (Materials and Methods) to score the 
GFP de-repression 96 hours post-transduction. Initial experiments were carried out with scrRNA to 
determine the optimum conditions for transduction (Supplementary S5). FACS data for optimization 
are given in Supplementary S6. The best condition chosen was MOI of 2.0 with polybrene 
concentration of 8 μg/ml and serum-free media with puromycin concentration of 2 μg/ml, where a 
transduction efficiency of 65% was achieved. Once the conditions for transduction were optimized, 
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RNAi screening was performed with selected factors given in Table 1. The screening was performed 
in triplicates and the percentage of GFP expressing cells was assessed by FACS. In order to be 
considered a candidate hit, three conditions were followed: i) Number and percentage of GFP cells 
should pass the median quartile cut-off; ii) Statistical significance based on one-tailed t-test; iii) At 
least two shRNAs per gene should pass the above conditions. As can be observed from Figure 2, 7 
genes were obtained as candidate hits from the screening: Chd4, G9a, H2afy, Kat5, Prdm16, Tal1 
and Tdrd3. Details of candidates and the repsective p-values are given in Supplementary S7 while 
graph of GFP percentages of other shRNAs from screening are given in the Supplementary S8.  
Some of the genes such as Chd4, G9a, H2afy and Prdm16 have well described roles in 
epigenetic silencing. However, Kat5 was particularly interesting because of its role as an 
acetyltransferase. FACS data of GFP from Kat5 knockdown cells from screening is given in 
Supplementary S9. In addition to Kat5 knockdown cell line, cell lines with Dnmt1, Hdac1 and 
Suv39h1 knockdowns were made to compare the GFP de-repression. Strikingly, Figure 3, shows that 
Kat5 knockdown cells have higher percentage of GFP+ cells than the knockdowns of known 
silencing factors. We then checked for the efficiency of Kat5 knockdown using qPCR and observed a 
50% knockdown at the mRNA level (Figure 4a). Furthermore, we were also able detect more GFP 
expression in Kat5 knockdown cells at mRNA level as compared to negative control (Figure 4b). 
 
Figure 2. Graph showing percentage of GFP expressing cells for candidate hits 
obtained from RNAi screening following the above mentioned conditions. Error 
bars and asterisks indicate the SEM and significance level based on one-tailed t-test 
respectively. Screening was done in 3 independent biological replicates. [* −p ≤ 0.05; 
** −p ≤ 0.01] (GFP control—TSA treated; Negative control—TagRFP shRNA) 
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Figure 3. Graph showing percentage of GFP expressing cells for Kat5, Dnmt1, 
Hdac1 and Suv39h1 knockdown cell lines. Error bars and asterisks indicate the 
SEM and significance level based on one-tailed t-test respectively. Samples were 
averaged over triplicates [* −p ≤ 0.05; ** −p ≤ 0.01; *** −p ≤ 0.001] (GFP control—
TSA treated; Negative control—TagRFP shRNA). 
 
Figure 4. Partial knockdown of Kat5 leads to alleviation of GFP silencing. a) qPCR 
data showing the fold change for Kat5 expression; b) qPCR data showing the fold 
change for GFP expression. Error bars and asterisks indicate the SEM and 
significance level based on one-tailed t-test respectively. 4 replicates were used in 
both cases and expression level was normalized to that of β-actin [* −p ≤ 0.05; ** −p 
≤ 0.01; *** −p ≤ 0.001]  
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3.2. Distribution of H3K9me3 was unaltered in Kat5 knockdown cells 
We then wanted to characterize the role of Kat5 in silencing. We first asked if the distribution of 
chromocenters or the classic hallmark of silencing, H3K9me3, could be altered. We performed 
microscopy at 100x magnification to visualize the distribution of H3K9me3, and the DAPI stained 
chromocenters. We observed that the loss of Kat5 did not have an apparent effect on the distribution 
of H3K9me3 (Figure 5a). In addition, we imaged the cells at 10x magnification and calculated the 
intensity of H3K9me3. Indeed, differences were not statistically significant (Figure 5b) further 
confirming that the loss of silencing does not occur from reduction of H3K9me3 levels and apparent 
heterochromatin structure. Furthermore, this observation was validated by Western blot which 
indicated that the levels of H3K9me3 remain unchanged by Kat5 knockdown (Figure 6a and b). 
3.3. Kat5 knockdown cells showed reduced levels of histone H4 acetylation 
Earlier reports in yeast suggested that acetylation patterns of specific residues in H4 were 
important for maintenance of silencing at heterochromatin and telomeres [23,24]. Since Kat5 can 
acetylate 4 lysine residues in H4 tail, namely, H4K5, -K8, -K12 and -K16 [19], we hypothesized that 
loss of Kat5 can modify the patterns of H4 acetylation and hence could disrupt the silencing at the 
CMV promoter thereby resulting in GFP expression. We extracted histones from Kat5 knockdown 
and scrRNA cell lines and performed Western blot for 5 different modifications: i) H3K9me3, ii) 
H4K5ac; iii) H4K8ac; iv) H4K12ac and v) H4K16ac, with total histone H3 as loading control. We 
were able to validate that H3K9me3 was unaltered supporting the results from microscopy. 
Additionally, we found that acetylation levels in Kat5 knockdown cells were lower than those in 
scrRNA-transduced cells (Figure 6a). Densitometric analysis was also performed by normalizing the 
intensities to that of H3 (Figure 6b) and the reduction in H4K16ac was observed to be significant, 
which provides a credible outcome to our hypothesis mentioned earlier. Based on these results, we 
could suggest that Kat5 might regulate silencing by maintaining the patterns of H4 acetylation. 
4. Discussion 
Our use of a mouse cell based system with a silenced GFP transgene provided a convenient 
model of epigenetically silenced locus in a mammalian system similar to that of the adenine or uracil 
marker in yeast or position-effect variegation in fruit flies. As a result, our study identified seven 
factors, Prdm16, Kat5, Tal1, Tdrd3, G9a, Chd4 and H2afy some of which have already been 
characterized for their roles in epigenetic silencing, which indeed validates our screening. 
Our study also identified two novel factors, TDRD3 and KAT5, whose role in silencing have 
been implicated before but reports on their mechanisms of action have not been well described. 
TDRD3 is a co-transcriptional activator which acts as an effector molecule in recognizing histone 
arginine methylation marks deposited by CARM and PRMT1 [25]. The only implication of its role in 
silencing is an indirect mechanism through its involvement in piRNA biogenesis, although the 
mechanism is not yet known [26]. We were particularly interested in studying the role of KAT5, 
specifically because it is an acetyltransferase. KAT5 is a histone lysine (K) acetyltransferase 
belonging to the MYST family that acetylates H4 at -K5, -K8, -K12, -K16; H3 at K14 and H2A at     
-K4 [19]. It is one of the components of human NuA4 complex [27] and has nucleosome binding 
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domain which aids in the formation of complexes involved in acetylation at nucleosomes [28]. In 
addition, it has been well studied for its role in DNA damage response through its interaction with 
various kinases. Most importantly, mutation of KAT5 has been linked to various cancers [28].  
 
 
Figure 5. Overall heterochromatin structure and H3K9 trimethylation is not 
affected by Kat5 knockdown. a) H3K9me3 staining and DAPI used for visualization 
of chromocenter distribution. Knockdown and Negative control: Cells with and 
without Kat5 knockdown; b) Box-plot of H3K9me3 intensities between the TagRFP 
shRNA (negative control) and Kat5 knockdown cells (ns—not significant). Images 
were taken at 10x magnification at 5 different positions each having at least 200 
cells and analysed using CellProfiler v2.1.1. Whiskers indicate the maximum and 
minimum quartiles. 
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Figure 6. Analysis of global levels of histone modifications in Kat5 knockdown. a) 
Western blot of different modifications at H4 and H3K9me3. Total H3 was used as 
a loading control. The intensities were calculated using ImageStudio™ v3.1; b) 
Densitometric analysis of Western blot with average intensity values from 
duplicates. Intensities were calculated using ImageStudio™ v3.1 and normalized to 
the intensities of total histone H3. Error bars and asterisks indicate the SEM and 
significance level based on one-tailed t-test respectively. [* −p ≤ 0.05; ** −p ≤ 0.01; 
ns—not significant]. 
Acetyltransferases, in general, have been associated with gene expression and transcriptional 
activation. However, our study identified Kat5 as putative silencing factor. This supports earlier 
reports which suggests that Kat5 may be associated with HDAC7 and KLF4 by forming a repressive 
complex in regulating the promoter of HDC [29]. In addition, involvement of Kat5 in silencing the 
expression of viral genes by repressing EIA promoter through H4 acetylation and down regulation of 
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Notch-IC via Kat5’s HAT activity have also been implicated. However, they have suggested that 
such acetylation of histones might be involved in recruitment of a repressive complex rather than a 
more direct outlook [30,31]. 
Reports suggested that Kat5 can bind to H3K9me3 [32]. We thus hypothesized that the level of 
H3K9me3 might be altered due to knockdown of Kat5, through which it might regulate silencing. 
However, we were able to observe no change in the distribution of H3K9me3 or any changes in the 
chromocenters between Kat5 knockdown and scrRNA cells. This was also confirmed by Western 
blot to assess the global levels of H3K9me3. 
Studies by Braunstein et al., 1996, on Saccharomyces cerevisae suggested that acetylation of H4 
is very important for the maintenance of heterochromatin structure. They hypothesized that specific 
patterns of histone acetylation, especially at H4K5 and H4K12, play a significant role in silencing at 
heterochromatin. Besides, H4K12 acetylation is observed at higher level as compared to acetylations 
at other residues. The same pattern of acetylation was found at the centric heterochromatin of 
Drosophila melanogaster. Indeed, such patterns of acetylation were observed only at the 
transcriptionally silenced locus as compared to the active regions [23]. In addition, a study showed 
that loss of Hat1, also called as Kat1, in Schizosaccharomyces pombe resulted in the loss of silencing 
at Telomeres. Hat1 is member of MYST family of acetyltransferases, similar to Kat5, and is involved 
in acetylation of H4K12 and H4K5 [24]. Since Kat5 can acetylate 4 residues at histone H4, we 
hypothesized that Kat5 might be able to regulate silencing on a more direct context by maintaining 
the patterns of histone acetylation. Based on our results, where a reduction in the levels of acetylation 
was observed, it might be possible that Kat5 has a more direct role in silencing. This observation 
supports the results obtained by Gupta et al., where they observed that the H4 acetylation activity of 
Kat5 was important for silencing at EIA promoter locus [30]. Furthermore, the reduction at H4K16 
was statistically significant. This is an important observation because, in the context of mammals, 
acetylation at H4K16 is abundant and plays an important role in transcription. It negatively regulates 
the formation of 30nm fiber in chromatin and circumvents the mobilization of nucleosomes by 
impeding the function of ACF enzyme and ATP-dependent chromatin remodelling (ADCR)    
activity [33] which explains its role as an activating mark. Studies also indicate that normal levels of 
acetylation at H4K16 in male D. melanogaster was linked to highly expressed X chromosome. Such 
evidences might indicate the reason for unacetylated lysine 16 in yeast in promoting silencing [34]. 
Further, [23], suggested that the role played by H4K12ac in heterochromatin maintenance in S. 
cerevisae could be played by H4K16ac in the context of mammals and vice versa. The presence of a 
dedicated H4K16ac factor in mammals, MOF [35], adds credibility to the above hypothesis. Such 
patterns of histone acetylation might also exist as a synthetic lethality between H4K16 and      
H4K12 [23]. 
5. Conclusion 
Our study using a modified mouse cell line hosting an epigenetically silenced GFP reporter 
provided interesting results, although they were preliminary. Our aim was to find novel silencing 
factors and try to understand their possible molecular function. We were able to point out few factors 
which might possess a role in silencing, using a system which was previously used in yeasts with 
tremendous success leading to functional identification of hundreds of novel chromatin-associated 
factors and other proteins. Indeed, this methodology can now be extended to a genome-wide 
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approach through RNAi or the recently developed CRISPR system. Our screening suggested Kat5 as 
a silencing protein with an insight into its putative molecular mechanism. However, further 
experiments such as RNA and ChIP sequencing will have to be performed in order to confirm its role 
at a global level and to identify the involvement of other factors, if any. Additionally, mutational 
studies of specific residues of Kat5 should prove the catalytic function of Kat5 in epigenetic 
silencing. Further analysis of the proteins implicated in silencing through this screening should 
reveal novel mechanism of action in chromatin, if any and studying them in a more comprehensive 
manner in the context of cancer would provide new perspectives to their potential as drug targets. 
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